»

[Siforus]

Originally Posted by caroline I'm still holding onto my stock as well in hopes of FDA approval. This is my first stock purchased and I was so proud of myself because it looked like it was going well-

We bought this when we first started investing also. 2.31 buy in price.
Somewhat attached to our investments but not a lot of extra time to stay as current on things as we should.
Read the Google and Yahoo boards a lot.
Not sure but wasn't Heb going to have another meeting or conference,show this week.
Dr Carter speaks?
Also some folks have the current short sale information that I think tomorrow is the last day to cover for the period? Then PPS go back up to 1.80? Still learning this Short play stuff.

Hang tight Caroline........Ampligen is on it's way

What's this? FDA Approval Dates

HEB 10-31-2009 Hmmm

[dorkytom]

Originally Posted by Siforus: Not sure but wasn't Heb going to have another meeting or conference,show this week. Dr Carter speaks?

ITs actually the Health and Human Services CFS Advisory Committee.

Its done for today, and will continue throughout tomorrow.
See the agenda:
CFSAC Agenda - October 29-30, 2009

Carter was not there... but people on Yahoo forums said a representative from HEB spoke.

I wasn't able to watch it today... and the archive is not up yet, so i don't know specifics except for the agenda.

You can watch Day 2 live here tomorrow.

NIH VideoCasting Event Summary

Originally Posted by Siforus: Also some folks have the current short sale information that I think tomorrow is the last day to cover for the period? Then PPS go back up to 1.80? Still learning this Short play stuff.

I think your mistaking this with Options expiring (particularly Put Options). HEB has no options available for purchase. It could be that the reporting of short interest is tomorrow, but that has nothing to do with forcing people to cover.
(Please let me know if I'm wrong ... I'm always interested in learning something new)


I've been buying heb at all sorts of prices from 1.20- 2.30... everytime it drops and it drops a lot I just buy a little more. Been Waiting since May. I took a big loss today with GETA... poured the left over money into HEB today... so I really want this to come through. Now have about 10k shares.

Originally Posted by Siforus: What's this? FDA Approval Dates HEB 10-31-2009 Hmmm

I think thats just a random guess.... been tracking HEB daily and I never heard this date anywhere.
Of course if it happens to be that date... I'll be extremely happy.... I sent Kabilus a message inquiring where he obtained that date, I'll report when I hear a response.

[caroline]

Thanks for the encouragement Siforus!

[Siforus]

I have no idea what I'm talking about when it comes to short interest.
Still learning this aspect of trading.

Thanks for the the links dorkytom!

Something is definitely up today as the first hour of trading has over 2 millions shares and we are down 11 cents ? dropping even more as I write this.

Buy Buy Buy

[Trader and Surfer]

Hemispherx Biopharma Updates Chronic Fatigue Syndrome (CFS) Treatment and Commercial Application Programs
10 minutes ago - Globenewswire
Related Companies
Symbol Last %Chg
HEB 1.33 -8.28%

As of 9:55 AM ET 11/2/09
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced a two-prong CFS clinical mission for November and December 2009.
The Company plans to widen its ongoing clinical programs in CFS by accelerating collaborations with a consortium of researchers who have just discovered a retroviral link to Chronic Fatigue Syndrome (please see October 8, 2009, online issue of Science). A clinically validated test to detect retrovirus antibodies in patients plasma is also currently under development (please see US National Institutes of Health at: Retroviral Link to Chronic Fatigue Syndrome - National Cancer Institute). With the consortium of researchers at the Whittemore Peterson Institute, the Company is also now evaluating the defect in immunosurveillance in specific subsets of CFS patients in a clinical study entitled "Therapeutic Activation of NK lymphocytes to Alleviate Chronic Fatigue Syndrome." These immune defects may be due to the previously undetected retrovirus.
The Company also plans to complete all outstanding queries from the FDA regarding its New Drug Application (NDA) for Ampligen(R), an experimental therapeutic, during November and December, 2009. On May 26, 2009, the Company announced a delay on the Ampligen NDA which, at the time, had a PDUFA date of May 25, 2009. As noted in the 10-Q and 10-K filings at the time, the FDA did not request additional information from the Company at that time. However, several outstanding NDA items, requiring Hemispherx responses, existed at the time of the FDA delay as noted in the August 8, 2009, 10Q filing. Between March 9, 2009 and September 15, 2009, the Company issued six (6) new reports to the Agency spanning various subjects including a) clinical safety assessments, b) specialized pre-clinical toxicology reports, and c) abbreviated chemistry and manufacturing control reports. The Company believes that these reports may fully retire all Agency queries in these particular areas.
The Company also plans to submit four (4) additional reports on interrelated topics in November and December, 2009, which will include pharmacokinetic analyses in multiple lower animal species (primates, rodents, etc.) ("the Lovelace Laboratory Studies") and final validation reports of certain manufacturing procedures conducted at an independent facility, Hollister-Stier Laboratories in Spokane, WA. Some of these reports were recently cited in BioMedReports.com and the Science Business Exchange (October 15, 2009)

[buddyinny]

Seems HEB has been queried multiple times by FDA and to think of it HEB has not informed the public about such queries till date!!! How shameful!!!

Hemispherx Biopharma responding to FDA’s Ampligen questions - Philadelphia Business Journal:

Originally Posted by Trader and Surfer Hemispherx Biopharma Updates Chronic Fatigue Syndrome (CFS) Treatment and Commercial Application Programs 10 minutes ago - Globenewswire Related Companies Symbol Last %Chg HEB 1.33 -8.28% As of 9:55 AM ET 11/2/09 Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced a two-prong CFS clinical mission for November and December 2009. The Company plans to widen its ongoing clinical programs in CFS by accelerating collaborations with a consortium of researchers who have just discovered a retroviral link to Chronic Fatigue Syndrome (please see October 8, 2009, online issue of Science). A clinically validated test to detect retrovirus antibodies in patients plasma is also currently under development (please see US National Institutes of Health at: Retroviral Link to Chronic Fatigue Syndrome - National Cancer Institute). With the consortium of researchers at the Whittemore Peterson Institute, the Company is also now evaluating the defect in immunosurveillance in specific subsets of CFS patients in a clinical study entitled "Therapeutic Activation of NK lymphocytes to Alleviate Chronic Fatigue Syndrome." These immune defects may be due to the previously undetected retrovirus. The Company also plans to complete all outstanding queries from the FDA regarding its New Drug Application (NDA) for Ampligen(R), an experimental therapeutic, during November and December, 2009. On May 26, 2009, the Company announced a delay on the Ampligen NDA which, at the time, had a PDUFA date of May 25, 2009. As noted in the 10-Q and 10-K filings at the time, the FDA did not request additional information from the Company at that time. However, several outstanding NDA items, requiring Hemispherx responses, existed at the time of the FDA delay as noted in the August 8, 2009, 10Q filing. Between March 9, 2009 and September 15, 2009, the Company issued six (6) new reports to the Agency spanning various subjects including a) clinical safety assessments, b) specialized pre-clinical toxicology reports, and c) abbreviated chemistry and manufacturing control reports. The Company believes that these reports may fully retire all Agency queries in these particular areas. The Company also plans to submit four (4) additional reports on interrelated topics in November and December, 2009, which will include pharmacokinetic analyses in multiple lower animal species (primates, rodents, etc.) ("the Lovelace Laboratory Studies") and final validation reports of certain manufacturing procedures conducted at an independent facility, Hollister-Stier Laboratories in Spokane, WA. Some of these reports were recently cited in BioMedReports.com and the Science Business Exchange (October 15, 2009)

[Trader and Surfer]

so by the time HEB submits everything by say December, that pushes the FDA approval date to probably where? March-June 2010?

[Trader and Surfer]

Just averaged down today, anybody else do the same?

[buddyinny]

Knowing how FDA works, it cud prolong even more...

Originally Posted by Trader and Surfer so by the time HEB submits everything by say December, that pushes the FDA approval date to probably where? March-June 2010?

[Sharpie]

Added 20,000 shares yesterday at 1.1

Next target is 0.80 cents to add more.